NCT02147938

A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)

French Multicentre Observational Study of a Prospective Cohort of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 578 (actual)
• Sponsor: Astellas Pharma S.A.S. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Assessment in a real situation of the conversion conditions, the efficacy and the safety of the treatment with tacrolimus in renal transplant patients converted from the tacrolimus twice per day form (Prograf®) to the tacrolimus once per day form (Advagraf®) with follow-up at one year. Analysis of two groups of patients: patients converted from Prograf® to Advagraf® early (during the first 6 months post-transplantation) or late (between 6 and 12 months post-transplantation).

Conditions

• Renal Transplantation

Interventions

Type	Name	Description
DRUG	Tacrolimus	oral

Timeline

• Start date: 2014-07-17
• Primary completion: 2017-05-15
• Completion: 2017-05-15
• First posted: 2014-05-28
• Last updated: 2024-11-01

Locations

26 sites across 1 country: France